Keith W Pratz: Novel risk signature for AML treated with Azacitidine and Venetoclax

Keith W Pratz, Director of Leukemia at the Hospital of University of Pennsylvania, shared on X:

“Happy to share novel risk signature for AML treated with Azacitidine and Venetoclax. These data derived from VIALE-A trial demonstrate mutations in four genes (TP53, FLT-3, KRAS, and NRAS) predict patient outcomes more definitively than ELN2022 or ELN 2017.”

Rahul Bhansali, Hematology/Oncology Fellow at Penn Medicine – Abramson Cancer Center, shared this post, adding:

“Nice to see these data out! My takeaways:

1. TP53 still the bad player.
2. MDS-related mutations in the higher benefit group with Ven-aza with earlier recent studies of RUNX1, ASXL1, etc.
3. Waiting for more data on triplets and/or sequencing on FLT3 outcomes in this context.”

Sources: Keith W Pratz/X and Rahul Bhansali/X

Authors: Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, Andrew H. Wei, Brian A. Jonas, Vinod Pullarkat, Michael J. Thirman, Christan Récher, Andre C. Schuh, Sunil Babu, Xiaotong Li, Grace Ku, Zihuan Liu, Yan Sun, Jalaja Potluri, Monique Dail, Brenda Chyla, Daniel A. Pollyea

Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients With AML Treated With Venetoclax and Azacitidine